Streetbeat News

NAMS

NewAmsterdam Pharma Company N.V.

https://www.newamsterdampharma.com

Industry

Biotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Open

23.71

Mkt cap

2.6B

Volume

1.3M

High

24.00

P/E Ratio

-9.13

52-wk high

27.29

Low

22.76

Div yield

N/A

52-wk low

15.19

NewAmsterdam Pharma's stock plummeted despite positive results from a cholesterol study showing a 50% reduction in LDL. The market reaction suggests other factors may be influencing investor sentiment.

Portfolio Pulse from

November 20, 2024 | 3:30 pm

NewAmsterdam Pharma (NASDAQ:NAMS) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have set a 12-month price target range of $31.00 to $37.00, with an average of $33.75, slightly up from the previous $33.00. The company shows strong revenue growth but faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 1:00 pm

Piper Sandler has reiterated its Overweight rating on NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:30 pm

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating for NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a price target of $31.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:00 pm

Needham has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS), highlighting its cholesterol drug obicetrapib as a potential blockbuster. The drug showed significant LDL-C reduction in trials, and Needham has set a Buy rating with a $36 price target. Obicetrapib could generate over $2 billion in sales, targeting 30 million patients.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 5:33 pm

Needham analyst Serge Belanger has initiated coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and set a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 10:46 am

NewAmsterdam Pharma reported Q2 revenue of $2.3 million and an EPS of $(0.41).

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:40 pm

NewAmsterdam Pharma (NASDAQ:NAMS) released positive topline data from its Phase 3 BROOKLYN trial for obicetrapib, showing significant LDL-C reduction in HeFH patients. Despite meeting primary endpoints, the stock experienced volatility, closing 8.35% lower. Analyst William Blair remains confident in the drug's potential, reiterating an Outperform rating.

Portfolio Pulse from Vandana Singh

July 30, 2024 | 7:10 pm

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a $31 price target.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 1:39 pm

NewAmsterdam Pharma shares are trading lower after the company announced its phase 3 BROOKLYN trial results for Obicetrapib in reducing LDL-C.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.